Inhibrx Biosciences, Inc. (INBX)Healthcare | Biotechnology | La Jolla, United States | NasdaqGS
92.17 USD
-0.85
(-0.909%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 91.52 -0.65 (-0.645%) ⇩ (July 13, 2026, 4:27 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:24 a.m. EDT
The investment case for Inhibrx is currently paralyzed by a stark disconnect between its biotech potential and its financial reality. Fundamentally, the company is a classic speculative vehicle: it has negligible revenue ($1.3 million), negative earnings, and a massive cash burn, resulting in a negative book value and a forward P/E that is mathematically undefined. While the price has rallied 64% year-to-date, this is driven entirely by the hope of a clinical trial success or a strategic acquisition, not by sustainable business operations. The balance sheet is fragile, with debt nearly matching cash reserves, leaving little room for error if development milestones slip. The short-term outlook remains precarious. Despite a recent surge in price, the statistical forecasting models offer almost no directional guidance, reflecting the chaotic nature of the stock's movement. Options activity confirms this uncertainty; traders are buying deep out-of-the-money calls for a moonshot rally while simultaneously placing heavy hedges at much lower price levels, signaling that the market expects a binary event—either a massive spike or a sharp correction. With no dividend to provide income and a high beta amplifying every move, this is not a stable holding. It remains a high-risk speculation suitable only for investors willing to accept total loss in exchange for a lottery ticket on a drug approval. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.233969 |
| AutoTheta | 0.325852 |
| AutoARIMA | 0.614340 |
| MSTL | 1.591554 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 8.94 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.086 |
| Excess Kurtosis | -0.74 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.084 |
| Market Cap | 1,352,169,856 |
| Forward P/E | -14.63 |
| Beta | 3.43 |
| Website | https://inhibrx.com |
As of July 11, 2026, 4:24 a.m. EDT: Speculators are positioning for extreme volatility rather than a specific directional outcome. Near-term expirations show heavy out-of-the-money call open interest at strikes like $120 and $150, suggesting a bullish gamma squeeze or binary event expectation. However, deep-dated January 2027 data reveals a massive 'put wall' at the $60 strike with significant volume spikes at lower strikes ($25-$30), indicating a hedge against a severe crash or a bet on a prolonged downtrend. The implied volatility landscape is bifurcated: high IV on deep OTM calls suggests a dream scenario, while the low IV on deep ITM puts reflects a lack of pricing for a catastrophic drop, creating a volatile environment where both sides are hedging against opposite extremes.
| Attribute | Value |
|---|---|
| 52 Week Change | 3.0509582 |
| Address1 | 11,025 North Torrey Pines Road |
| Address2 | Suite 140 |
| All Time High | 155.29 |
| All Time Low | 10.8 |
| Ask | 114.86 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Daily Volume10 Day | 429,530 |
| Average Daily Volume3 Month | 472,639 |
| Average Volume | 472,639 |
| Average Volume10Days | 429,530 |
| Beta | 3.426 |
| Bid | 66.21 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | -1.44 |
| City | La Jolla |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 92.165 |
| Current Ratio | 6.463 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 94.31 |
| Day Low | 88.77 |
| Display Name | Inhibrx Biosciences |
| Earnings Timestamp | 1,778,788,800 |
| Earnings Timestamp End | 1,786,564,800 |
| Earnings Timestamp Start | 1,786,564,800 |
| Ebitda | -120,706,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -11.362 |
| Enterprise To Revenue | 1,054.931 |
| Enterprise Value | 1,371,410,816 |
| Eps Current Year | -9.26 |
| Eps Forward | -6.3 |
| Eps Trailing Twelve Months | -8.39 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 104.2686 |
| Fifty Day Average Change | -12.1036 |
| Fifty Day Average Change Percent | -0.11608096 |
| Fifty Two Week Change Percent | 305.09583 |
| Fifty Two Week High | 155.29 |
| Fifty Two Week High Change | -63.124992 |
| Fifty Two Week High Change Percent | -0.40649748 |
| Fifty Two Week Low | 20.55 |
| Fifty Two Week Low Change | 71.615005 |
| Fifty Two Week Low Change Percent | 3.4849153 |
| Fifty Two Week Range | 20.55 - 155.29 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,716,989,400,000 |
| Float Shares | 8,369,471 |
| Forward Eps | -6.3 |
| Forward P E | -14.629365 |
| Free Cashflow | -89,107,872 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 109 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -100,068,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.23156999 |
| Held Percent Institutions | 0.82235 |
| Implied Shares Outstanding | 14,671,186 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-08-19 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California. |
| Long Name | Inhibrx Biosciences, Inc. |
| Market | us_market |
| Market Cap | 1,352,169,856 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_1873020488 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -130,185,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,364,567,009 |
| Number Of Analyst Opinions | 2 |
| Open | 90.85 |
| Operating Cashflow | -131,925,000 |
| Operating Margins | -94.65462 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 858 795 4220 |
| Post Market Change | -0.6450043 |
| Post Market Change Percent | -0.69983643 |
| Post Market Price | 91.52 |
| Post Market Time | 1,783,974,457 |
| Previous Close | 93.01 |
| Price Eps Current Year | -9.953024 |
| Price Hint | 2 |
| Price To Book | -64.00347 |
| Price To Sales Trailing12 Months | 1,040.1306 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.105 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.845001 |
| Regular Market Change Percent | -0.908506 |
| Regular Market Day High | 94.31 |
| Regular Market Day Low | 88.77 |
| Regular Market Day Range | 88.77 - 94.31 |
| Regular Market Open | 90.85 |
| Regular Market Previous Close | 93.01 |
| Regular Market Price | 92.165 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 232,872 |
| Return On Assets | -0.36055002 |
| Return On Equity | -3.54689 |
| Revenue Per Share | 0.084 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 14,671,186 |
| Shares Percent Shares Out | 0.235 |
| Shares Short | 3,447,032 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,179,335 |
| Short Name | Inhibrx Biosciences, Inc. |
| Short Percent Of Float | 0.314 |
| Short Ratio | 10.24 |
| Source Interval | 15 |
| State | CA |
| Symbol | INBX |
| Target High Price | 325.0 |
| Target Low Price | 230.0 |
| Target Mean Price | 277.5 |
| Target Median Price | 277.5 |
| Total Cash | 161,656,992 |
| Total Cash Per Share | 11.019 |
| Total Debt | 180,898,000 |
| Total Revenue | 1,300,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -8.39 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 79.85452 |
| Two Hundred Day Average Change | 12.310478 |
| Two Hundred Day Average Change Percent | 0.15416132 |
| Type Disp | Equity |
| Volume | 232,872 |
| Website | https://inhibrx.com |
| Zip | 92,037 |